Variable | N | Progression (n) | 5-year PFS rate (95% CI) | HR (95% CI)* | P value*† |
Age at diagnosis | |||||
<50 years | 68 | 11 | 83.7% (71.6% to 91%) | 1 | 0.214 |
>50 years | 114 | 26 | 78.3% (68.7% to 85.2%) | 1.56 (0.77 to 3.17) | |
Race | |||||
White | 131 | 27 | 80.4% (71.8% to 86.6%) | 1 | 0.986 |
Non-white | 34 | 6 | 83.2% (63.5% to 92.8%) | 0.99 (0.41 to 2.42) | |
Stage (FIGO) | |||||
IA | 81 | 7 | 90.7% (81.3% to 95.5%) | 1 | <0.001 |
IC1 | 39 | 6 | 83% (65.9% to 92%) | 1.87 (0.63 to 5.57) | |
IC2 | 16 | 5 | 67.7% (31% to 87.8%) | 4.21 (1.34 to 13.30) | |
IC3 | 25 | 12 | 55.2% (29.7% to 74.7%) | 7.16 (2.81 to 18.23) | |
IIA | 9 | 4 | 53.3% (17.7% to 79.6%) | 6.7 (1.96 to 22.94) | |
IIB | 12 | 3 | 83.3% (48.2% to 95.6%) | 3.5 (0.90 to 13.55) | |
Risk category | |||||
Low risk (IA/IC1) | 120 | 13 | 88.2% (80.5% to 93%) | 1 | <0.001 |
High risk (IC2/IC3/IIA/IIB) | 62 | 24 | 63.8% (48.2% to 75.8%) | 4.37 (2.22 to 8.60) | |
Concordant endometriosis | |||||
Absent | 60 | 10 | 80.9% (67% to 89.4%) | 1 | 0.257 |
Present | 122 | 27 | 80.2% (71.3% to 86.5%) | 1.52 (0.73 to 3.14) | |
p53 IHC | |||||
Aberrant | 3 | 3 | Not reached | 1 | <0.001 |
Wild-type | 63 | 13 | 84.2% (71.6% to 91.5%) | 0.06 (0.02 to 0.25) | |
MMR IHC | |||||
Retained | 76 | 18 | 78.8% (66.5% to 87%) | 1 | 0.815 |
Deficient | 6 | 1 | 83.3% (27.3% to 97.5%) | 0.75 (0.10 to 5.68) | |
Post-operative chemotherapy‡ | |||||
None | 15 | 2 | 92.9% (59.1% to 99%) | 1 | 0.687 |
Received | 165 | 34 | 79.8% (72.2% to 85.5%) | 1.40 (0.34 to 5.86) | |
Platinum cycles‡ | |||||
0 | 15 | 2 | 92.9% (59.1% to 99%) | ||
1–3 | 19 | 0 | 100% | ||
>3 | 146 | 34 | 77.4% (69.2% to 83.7%) |
*If a variable contains certain levels event=0, then there is no HR or p value provided.
†P value obtained by applying permutation log-rank test with 5000 permutation times if events count n <3.
‡‘Post-operative chemotherapy’ and ‘Platinum cycles’ related variables are analyzed using landmark analysis with landmark time set to be 4 months.
FIGO, Federation of Gynecology and Obstetrics; IHC, immunohistochemistry; MMR, mismatch repair; PFS, progression-free survival.